Moreover, this therapeutic strategy shows potential for extending its benefits to other solid tumours, such as pancreatic, and biliary cancers, cholangiocarcinoma, and pancreatic ductal adenocarcinoma, offering promising results in combatting various types of cancer.11,12 Several particular inhibitors of CDK4 and CDK6 have gained approval from the USFDA for the progressive ER+, HER2-negative breast cancer treatment. The gene discussed is CDK4; the disease is cancer.